67 results about "Cytoskeleton" patented technology

The invention provides a myopia grading method driven by coupling of mechanical and morphological characteristics of corneal cells, and belongs to the technical field of myopia eye disease diagnosis and occurrence and development mechanisms based on artificial intelligence. The surface topography, Young modulus, adhesive power and other mechanical characteristics of corneal cells of patients with low, medium and high myopia are measured, corneal cell surface topography images obtained by an atomic force microscope are used as a cytoskeleton quantitative analysis data set, and edge extraction, brightness detection and multi-scale image segmentation methods are utilized to determine the surface topography of the corneal cells of the patients with low, medium and high myopia. The overall cytoskeleton distribution characteristics are quantified through the cytoskeleton region average complexity and cytoskeleton region average similarity, the method does not depend on dyeing, the tissue structure of the cytoskeleton can be evaluated more comprehensively, the method is suitable for more diversified cytoskeleton structures including complex clusters, a myopia grading model is established, and the myopia grading efficiency is improved. And a more direct cellular-level experimental basis is provided for the research on the occurrence and development mechanism of myopia.

The present invention relates to use of expression vectors and other compounds in methods to disrupt the LInker of Nucleoskeleton and Cytoskeleton (LINC) complex, uncoupling the nucleus from its linkage to the cytoskeleton, resulting in amelioration of diseases caused by one or more Lmna mutations, so-called laminopathies. More particularly, the invention relates to the expression of dominant negative SUN domain protein and / or dominant negative KASH domain protein to disrupt, for example, the LINC complex in cardiomyocytes for suppressing disease progression in dilated cardiomyopathy (DCM).

The present invention provides molecules that bind to cellular components or parts thereof (e.g., filaments or histones forming the cytoskeleton or nucleoskeleton) that are exposed to the extracellular environment upon cell death, which are specifically observed in diseased tissues, and simultaneously bind to target molecules on or in cells that act specifically in tissues where cell death is observed, such as diseased tissues, abnormal tissues, etc. The molecules of the present invention are useful as drugs that provide significant therapeutic or preventive effects while reducing side effects.

The present invention relates to use of expression vectors and other compounds in methods to disrupt the Linker of Nucleoskeleton and Cytoskeleton (LINC) complex, uncoupling the nucleus from its linkage to the cytoskeleton, resulting in amelioration of diseases caused by one or more Lmna mutations, so-called laminopathies. More particularly, the invention relates to the expression of dominant negative SUN domain protein and / or dominant negative KASH domain protein to disrupt, for example, the LINC complex in cardiomyocytes for suppressing disease progression in dilated cardiomyopathy (DCM).

To provide compositions and methods for treating skin wounds, disorders and diseases.SOLUTION: The disclosure relates, in part, to a pharmaceutical composition comprising one or more polynucleotide species suitable for enhancing, increasing, augmenting, and / or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and / or lysyl hydroxylase 3 polypeptide and / or Keratin type I cytoskeletal 17 polypeptide in a subject. The disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.SELECTED DRAWING: Figure 3

The invention belongs to the field of biotechnology and reproductive medicine, and relates to an application of a cytoskeletal regulatory factor ROCK2 in remodeling male reproductive hormone synthesis, the application is to prepare a preparation for regulating male reproductive hormone synthesis, the preparation is a gene silencing preparation, the active component of the preparation is a small interfering RNA molecule aiming at ROCK2, and the active component of the preparation is a small interfering RNA molecule aiming at ROCK2. By inhibiting expression and activity of ROCK2 in a target cell, enrichment of a cortex F-actin network in a cell cortex and formation of a ring structure are promoted, the level of a phosphorylated myosin light chain is up-regulated, and then the targeted transport efficiency of cholesterol in the cell to mitochondria is enhanced. According to the present invention, the structure is complete, the function is complete, the skeleton stability and the hormone synthesis function of the Redis cell are effectively maintained through the specific inhibition of the ROCK2 expression, the technical threshold and the time cost of the drug screening and evaluation are reduced through the established standardized detection system, and the controllability and the safety of the hormone regulation process are ensured.

The invention belongs to the cross technical field of cell engineering, nano-drugs and biological manufacturing, and particularly discloses a drug-loaded vesicle based on denucleated cells as well as a preparation method and application of the drug-loaded vesicle. According to the invention, a cell suspension and a cytoskeleton relaxant are co-incubated to relax an actin skeleton and weaken nucleoplasm connection; then loading the treated cell suspension on a multi-layer discontinuous density gradient centrifugal medium, realizing physical separation of cell nucleuses and cytoplasm through high-speed centrifugation according to buoyancy density difference, and collecting components of a specific interface to obtain high-purity denucleated cells with a complete membrane structure; then co-incubating the denucleated cells and ROS response type lipidosome (co-carrying therapeutic siRNA and a sound-sensitive agent Ce6) prepared in advance, so that the lipidosome is wrapped or anchored by a denucleated cell membrane; finally, the composite system is subjected to extrusion treatment through a microporous membrane, the drug-loaded vesicles uniform in particle size and stable in structure are obtained, and the drug-loaded vesicles are suitable for various application scenes such as anti-tumor treatment and RNA vaccine delivery.

The application belongs to the field of biological medicine, and provides application of miR-152 as a target in preparation of a drug for treating podocytopathy and the drug. Specifically, the application relates to application of miR-152 as a therapeutic target and / or a drug screening target in preparation of a drug for treating podocytopathy and a drug for treating FSGS nephropathy. The miR-152 inhibitor can inhibit high expression of miR-152 in kidney tissues of podocytopathy or FSGS nephropathy, inhibit down-regulation of synaptopodin protein, RhoA protein and 14-3-3 beta protein expression, protect stability of a cytoskeleton of a podocyte in kidney tissues, and delay progressive development of FSGS disease. The application provides a new therapeutic target for treatment of FSGS disease, and has important social and economic significance.

The invention discloses a composition for promoting tissue regeneration and injury repair and application thereof. Experiments find that macrophages are more easily polarized to M2 under mechanical stimulation, meanwhile, molecules CCM3 on adhesion spots are reduced, further molecular dynamics simulation finds that combination of CCM3 protein and paxilin protein is reduced and combination of FAK protein and paxilin protein is increased under certain mechanical stimulation, and meanwhile, cytoskeleton rearrangement is obvious. The invention clarifies the molecular mechanism of the influence of mechanical stimulation on cell behavior, and thus can be used for developing a novel regeneration treatment method.

This invention discloses the application of a PDLIM2 gene overexpression viral vector in the preparation of drugs for treating podocyte disease, wherein the nucleotide sequence of the PDLIM2 gene is shown in SEQ ID NO:1. This invention is the first to discover and verify the core role of the PDLIM2 gene in podocyte protection, confirming its significant downregulation in DKD and FSGS disease models, and demonstrating through functional experiments that PDLIM2 overexpression can effectively stabilize the podocyte cytoskeleton, inhibit apoptosis, and reduce proteinuria, thus establishing it as a key target gene for the treatment of podocyte disease. This invention is the first to intervene at the gene level in the core link of podocyte damage—cytoskeleton stability. By specifically upregulating the expression of PDLIM2 in podocytes, it directly enhances their intrinsic cytoskeleton support and anti-damage ability, achieving a fundamental shift in treatment strategy from "symptomatic support" to "causal repair."

Hypomelanosis of Ito is a clinical term for patients with mosaic syndromes characterized by skin hypopigmentation and developmental disorders. The genetic causes of these rare diseases remain largely unclear. Here, we report that GNA13 is a new gene that causes Hypomelanosis of Ito. We identified an identical mutation in this gene in four unrelated patients exhibiting pigmentary mosaicism. In depth functional investigations revealed that this is an activatory mutation that alters the cytoskeleton and morphology of melanocytes via a hyperactivation of the RHOA / ROCK signalling pathway. Our results also indicate that this pathology does not necessarily originate from a decreased production of melanin, but can originate from a defect in melanosome transfer to keratinocytes due to cell shape alterations. Thus, our findings suggest for the first time a mechanism by which the clinical symptoms of patients with Hypomelanosis of Ito appear, and pave the path for new therapeutic approaches. Altogether, the present invention relates to a method for treating a patient suffering from hypomelanosis of Ito by administering a ROCK inhibitor and / or RHOA inhibitor.

This invention discloses the pharmaceutical applications of a P2Y11-specific inhibitor and compositions containing it, belonging to the field of biomedical technology. This invention discloses for the first time the use of NF157 in the preparation of drugs related to the treatment of HD5-induced pathogen infection. In combating pathogen infection, NF157 can specifically inhibit the binding of P2Y11 to HD5, thereby eliminating the role of HD5 in regulating cytoskeleton rearrangement and promoting filopodia formation, thus becoming a key link in interrupting pathogen infection. By preventing the formation of filopodia, NF157 effectively blocks the bacterial capture pathway, showing significant intervention effects on some pathogens that lack adhesion devices and flagella and rely on cellular pseudopodia capture for invasion.

The invention discloses an artificial cell and a preparation method thereof as well as a bionic tissue and a preparation method thereof, an aqueous dispersion of a negative electricity nanometer material is sprayed into an aqueous phase receiving bath containing a cationic polyelectrolyte and a surfactant through a gas-liquid shearing microfluidic technology, and one-step construction of an artificial cell membrane and a cytoskeleton is realized. According to the method, the internal skeleton enhanced artificial cell is constructed in a water phase by a one-step method by utilizing the electrostatic interaction of the negative electricity nano material and the cationic polyelectrolyte, and the method has the characteristics of convenience in preparation and excellent stability. By introducing different functional materials, multifunctional integration of the artificial cell can be realized. Meanwhile, the adhesion inducer is added, so that a bionic tissue can be further constructed, and the bionic tissue integrates excellent mechanical properties of the artificial cells and can bear disturbance to a certain degree without disintegration.

The invention provides a molecular self-assembly integrin patch for regulating and controlling mechanical signals of cells as well as a preparation method and application of the molecular self-assembly integrin patch, and an extracellular matrix (ECM) bionic cell patch is constructed through a molecular self-assembly technology. According to the patch, a laminin-derived integrin binding ligand is extended and self-assembled through an N-terminal aromatic amino acid to form a fibrous nano network, and the patch has controllable nano-scale ligand distribution, network viscoelasticity and stability, and can specifically activate integrin beta1 at the top end of MSC (mesenchymal stem cell), so that a mechanical signal is conducted from a cell membrane to a cell nucleus. The process coordinates cytoskeleton reconstruction, nuclear deformation and chromatin rearrangement, and finally drives the MSC to efficiently differentiate into neuron-like cells under the condition of no exogenous gene or chemical induction, so as to express nerve markers such as TUBB3 and present functional characteristics such as spontaneous calcium transient. The cell patch can be widely applied to nerve regeneration, tissue engineering, disease model construction and intelligent biological material development.

The invention belongs to the technical field of biology, and particularly relates to a cytoskeleton for promoting proliferation of corneal limbal stem cells. The raw materials of the cytoskeleton provided by the invention are chitosan and sodium hyaluronate, and the cytoskeleton has good biocompatibility and biological activity, can simulate the characteristics of an extracellular matrix, provides necessary physical and chemical support for stem cells, and does not cause immune response or cytotoxicity. The addition of the magnetic nanoparticles further enhances the performance of the cytoskeleton. Directional arrangement under the action of a magnetic field can provide structural support closer to an in-vivo microenvironment for cells, and adhesion and proliferation of the cells are promoted. The cell scaffold provided by the invention can provide a good growth microenvironment for the corneal limbus stem cells, and is beneficial to solving the problem that the corneal limbus stem cells are easy to lose activity and function in in-vitro culture.

The invention discloses application of mitochondrion Rab32 in preparation of a medicine for treating chronic sleep deprivation and a research method of the mitochondrion Rab32, and belongs to the technical field of biological medicine. A chronic sleep deprivation mouse model is established, the relationship between mitochondria Rab32 and in-vivo protein change of an SD mouse is researched, and the result shows that the mitochondria Rab32 participates in cytoskeleton protein function regulation and control and participates in neuronal synaptic regeneration by anchoring Sptan1 in cells. Rab32 is a key molecule for mediating neuron synaptic regeneration of SD mice and adjusting synaptic plasticity and cognitive impairment, and the research result may provide a new target for treatment of SD-related cognitive impairment in future.

The application relates to the technical field of biomedical engineering, and particularly discloses a method for extracting binary condensate immune signals, which comprises the following steps: screening disease-related high-expression genes by using a disease model, a normal model and a drug treatment model; screening important protein molecules based on the high-expression genes by using a nucleic acid-protein affinity analysis method; constructing a fusion carrier based on cytoskeleton proteins, important protein molecules and green fluorescent protein tracing; and identifying risk genes and possible downstream proteins associated with condensates by spatial omics imaging based on the fusion carrier of the disease model, the normal model and the drug treatment model, and quantifying the condensation process of the condensates. The application reduces the influence of problems such as condensate state destruction and spatial distribution information loss, and accurately realizes in-situ spatial omics imaging and analysis of an immune microenvironment evolution process of a complex disease.

The invention belongs to the field of cell measurement, and discloses a high-precision rod-shaped bacterial cell length measurement method, which comprises the following steps: S101, segmenting an image containing bacterial cells to be measured to obtain a mask image and a flow field image; s102, separating a mask and a flow field of each bacterial cell in the mask image and the flow field image to obtain a mask of a single bacterial cell and a flow field of a single bacterial cell; s103, respectively acquiring a smooth curve skeleton of each bacterial cell based on the mask and the flow field; s104, extending the smooth curve skeleton to the edge of the cell to obtain a cytoskeleton; and S105, calculating the length of the cytoskeleton. The high-precision rod-shaped bacterial cell length measurement method provides a high-precision, rapid and automatic solution for rod-shaped bacterial cell length measurement.

The application discloses a kind of drugs for treating glucocorticoid glaucoma.The application finds by experiment, Rho kinase inhibitor can inhibit RhoA-ROCK signal pathway, destroy glucocorticoid-induced cytoskeleton remodeling and reduce extracellular matrix deposition.At the same time, 10 μM or less concentration, no toxic side effects to cell growth, while significantly inhibiting RhoA-ROCK signal pathway.The experimental results suggest that RKI1447 can change the morphology of trabecular meshwork cells and inhibit cell migration, thereby regulating aqueous humor drainage, reducing intraocular pressure, and thereby treating glucocorticoid glaucoma.The application provides the application of Rho kinase inhibitor RKI1447 in the preparation of glucocorticoid glaucoma drugs.

The invention discloses application of a disulfide death inhibitor in a medicine and the medicine, and relates to the technical field of medicines, in particular to application of the disulfide death inhibitor in preparation of a medicine for treating hepatic ischemia-reperfusion injury, and the disulfide death inhibitor is 2-deoxy-D-glucose or tris (2-carboxyethyl) phosphine. It is found for the first time that the disulfide death inhibitor (2-deoxy-D-glucose and tris (2-carboxyethyl) phosphine) has a remarkable treatment effect on the hepatic ischemia reperfusion injury, and the 2-deoxy-D-glucose and the tris (2-carboxyethyl) phosphine can effectively relieve sulfide stress in hepatic cells and cytoskeleton shrinkage caused by hepatic ischemia; further, the disulfide death of liver cells is reduced, and the liver injury recovery is favorably promoted; therefore, the disulfur death inhibitor is applied to preparation of the medicine for treating the hepatic ischemia reperfusion injury, and a new method is provided for clinical prevention and treatment of the hepatic ischemia reperfusion injury.

The invention belongs to the technical field of biology, and discloses a preparation method and application of a cell culture solution containing nano bubbles. The preparation method comprises the following steps: transferring a cell culture solution into a suitable container; the container is placed in a high-pressure cavity, and air in the high-pressure cavity is completely exhausted by introducing gas; continuously introducing gas to maintain the pressure state in the high-pressure cavity; the pressure in the high-pressure cavity is reduced by slowly releasing the gas, so that the cell culture fluid containing the nanobubbles is obtained. The invention further provides the cell culture fluid containing the nano bubbles prepared by the method and application of the cell culture fluid in delaying cell senescence. The method disclosed by the invention is simple and easy to implement, and the prepared cell culture fluid containing the nanobubbles can be used for remarkably reducing the aging positive cell rate and protecting the cell nucleus and cytoskeleton morphology of aging cells, and has a good anti-aging effect.

The present invention relates to the use of a polypeptide or its antibody binding fragment that can form an antigen-antibody complex in contact with a biological sample obtained from the patient in the preparation of a vascular endothelial cell damage detection reagent or kit; wherein the polypeptide or its antibody binding fragment includes at least two selected from the following groups: alpha enolase protein (ENO1), talin 1 (TLN1), filament protein-A (FLNA), desmosome nexin (AHNAK), desmoglein-1 (DSG1), myosin light chain 1 (MYL1), heat shock protein 90β (HSP90AB1), cytoskeleton-associated protein 4 (CKAP4), membrane protrusion protein (MSN). The vascular endothelial cell autoantibodies of the present application can be used to diagnose vascular endothelial cell damage by simply detecting the titer in serum, and have very great clinical application value.

Cytoskeletal Network Based Computer Device for Predicting Tissue Cell Mechanics

A structurally intact red blood cell membrane, a preparation method therefor and the use thereof. Defining components of a release solution to lyse red blood cells allows for mild conditions, and can release protein components such as hemoglobin inside the red blood cells, remove cell properties thereof, keep the integrity of the cytoskeleton thereof and the activity of surface antigens of the membrane, and retain key blood group antigens on the surface of the red blood cell membrane while keeping the complete structure of the red blood cell membrane, thus reducing the problem of antigenicity reduction caused by fragmentation of the red blood cell membrane. After the red blood cells are lysed, nanoparticles are coupled to the surface of the red blood cell membrane, thus visualizing the agglutination reaction of the red blood cell membrane under the induction of antibodies. Using a fixed procedure to preserve engineered red blood cell biomembranes can effectively avoid damage to the engineered red blood cell biomembrane caused by ice crystals, ensure that the antigenicity of the membranes is not affected, allow for long-term preservation at room temperature, and prolong the shelf life to two years or more.

The application belongs to the technical field of micromanipulation biological modeling, and is based on a cell stretching tensor calculation method of dissipative particle dynamics, and the specific steps are as follows: step 1), a cell membrane model of dissipative particle dynamics is established; step 2), a simulation boundary condition and a type of ensemble integrator are determined; step 3), a cell membrane and a cytoskeleton model are aggregated; step 4), a microneedle penetration experiment platform is built in a simulation environment and the microneedle penetration experiment is started; and step 5), a strain of the cell in a penetration direction is calculated, the microneedle penetration simulation data are processed, finite strain theory is used for analysis and calculation, and a normal strain is output. The method can calculate the internal strain of the cell model under different parameters, and the effectiveness of the method is verified by comparison with the results in a real experiment.

The invention belongs to the technical field of respiratory disease targeted therapy and protein regulation and control, and relates to application of an ACTN2 protein enhancer in preparation of a medicine for preventing, relieving or treating asthma. The key'switch 'effect of the cytoskeleton protein ACTN2 in airway smooth muscle cell (ASMC) phenotype transformation is discovered and confirmed for the first time. The prior art mainly focuses on inflammatory pathways or bronchial relaxation, while the invention reveals that the expression down-regulation of ACTN2 is a key driving factor which causes the conversion of ASC from a resting systolic phenotype to a pathological synthetic phenotype. The discovery provides a brand new therapeutic target for asthma, especially refractory asthma accompanied by severe airway remodeling and hormone resistance.

This invention relates to the field of large-scale adipose-derived stem cell culture technology, and discloses a culture medium and method for promoting the efficient expansion of adipose-derived stem cells. The method includes: seeding adipose-derived stem cells in a serum-free basal culture medium and maintaining a normoxic environment; adding an expansion additive composed of a Rho-associated kinase inhibitor and a redox buffer component; during the window period when the ambient oxygen partial pressure decreases from normoxic to hypoxic, using the Rho-associated kinase inhibitor to relieve cytoskeleton tension to induce a physically relaxed cell membrane; and assisting the redox buffer component in constructing a reducing environment on the cell membrane surface in situ. This invention utilizes the dynamic synergy of membrane tension regulation and oxygen stress shielding to neutralize transient damage caused by sudden changes in ambient oxygen partial pressure, avoid transmembrane receptor conformational inactivation, inhibit premature cell aging at the mechanistic level, and ensure long-term stable expansion of adipose-derived stem cells without the need for heterologous protein protection.

This invention discloses Astragalus polysaccharide, extracted from Astragalus membranaceus. The average molecular weight of this Astragalus polysaccharide is 8-12 kDa, and its monosaccharides are mainly composed of galacturonic acid, glucose, galactose, and arabinose. This Astragalus polysaccharide is a GalA-type acidic polysaccharide that effectively reduces the deposition of immune complexes and the release of pro-inflammatory factors in renal tissue by regulating signaling pathways such as cGAS-STING. Simultaneously, it improves glomerular filtration function by stabilizing the podocyte cytoskeleton structure, exhibiting a synergistic protective therapeutic advantage. This invention also discloses a method for preparing this Astragalus polysaccharide.

Pesticidal mixtures comprising as active compounds 1) 1-[(1RS)-1,2-dimethylpropyl]-N-ethyl-5-methyl-N-pyridazin-4-yl-1H-pyrazole-4-carboxamide and 2) at least one further compound B selected from B.1) Succinate dehydrogenase inhibitors as defined in the specification; B.2) Inhibitors of oxysterol binding protein as defined in the specification; B.3) Inhibitors of complex Ill at Qi site selected from: a) florylpicoxamid, and b) fenpicoxamid; B.4) Strobilurins as defined in the specification; B.5) Inhibitors of C14-demethylase in sterol biosynthesis as defined in the specification; B.6) Inhibitors of cell division and cytoskeleton as defined in the specification, B.7) Other compounds of unknown mode of action as defined in the specification; and B.8) N-[[2-fluoro-4-[(2S,3S)-2-hydroxy-3-(3,4,5-trichlorophenyl)-3-(trifluoromethyl)pyrrolidin-1-yl]phenyl]methyl]cyclopropanecarboxamide; wherein component 1) and component 2) are present in a weight ratio of from 1000:1 to 1:1000; methods and use of these mixtures for combating invertebrate pests such as insects, arachnids, nematodes and / or harmful fungi in and on plants, and for protecting such plants being infested with pests and / or harmful fungi.